Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» relapsed or refractory large B-cell lymphoma
relapsed or refractory large B-cell lymphoma
Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Clinical Trials Arena
Gilead Sciences
Kite Pharma
Yescarta
clinical trials
CAR-T
relapsed or refractory large B-cell lymphoma
Flag link:
Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma
Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma
Businesswire
ASCO 2023
Gilead Sciences
Kite Pharma
Yescarta
relapsed or refractory large B-cell lymphoma
Flag link:
AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday
AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday
Fierce Biotech
AbbVie
Genmab
FDA
Roche
epcoritamab
bispecific antibodies
relapsed or refractory large B-cell lymphoma
Flag link:
